ong term hepatitis B immunity and response to a booster dose of hepatitis B vaccine in children born to hepatitis B carrier mothers
Recruiting
- Conditions
- Hepatitis BInflammatory and Immune System - Liver
- Registration Number
- ACTRN12606000394549
- Lead Sponsor
- ational Centre for Immunisation Research and Surveillance
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
Adolescents born to hepatitis B carrier mothers.
Exclusion Criteria
Mother not a hepatitis B carrierAll participants have hepatitis B serology at baselineOnly adolescents with HBsAb <10IU/ml given a booster dose of vaccine.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hepatitis B surface antibody measurement[At baseline and 2-4 weeks post vaccination]
- Secondary Outcome Measures
Name Time Method Hepatitis B surface antigen[Measurement at baseline]
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What immune response pathways are involved in long-term HBV immunity after booster vaccination in children born to carrier mothers?
How does the efficacy of a hepatitis B booster compare to standard vaccination protocols in preventing chronic HBV infection in high-risk infants?
What biomarkers predict sustained HBsAg seropositivity in ACTRN12606000394549 participants after HBV booster doses?
What are the long-term safety profiles and management strategies for adverse events after HBV booster administration in pediatric populations?
Are there combination therapies or adjuvants that enhance HBV vaccine-induced immunity in children with perinatal exposure?